ERIS Lifesciences Ltd (ERIS)

Eris Lifesciences Limited was incorporated on January 25 2007. Subsequently the name of the company was changed to Eris Lifesciences Private Limited on February 9 2007. Further the company was converted into a public limited company and the name was changed to Eris Lifesciences Limited on February 2 2017. The Company has a manufacturing plant located in Guwahati Assam and is presently engaged in the manufacturing distributing and marketing of branded pharmaceutical products. It has presence in high growth chronic sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this it has a portfolio of 112 Mother Brands across therapy areas. The company develops manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market IPM such as: cardiovascular antidiabetics vitamins gastroenterology and antiinfective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots 2059 Stockists and more than 500000 retail chemists.In 2007 the company launched Eris division focused on cardiology and diabetes segment. In 2008 the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009 the company launched Adura division focused on cardiology and diabetes segment. In 2011 the company launched Montana division focused on gynecology and pediatrics segment. In 2012 the company launched Inspira division focused on cardiology segment. In 2014 the company launched Victus division focused on antidiabetes segment. During the year the company set up manufacturing facility at Assam. In 2015 the company launched Eris 2 division focused on pain management segment.In 2016 the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited now Aprica Pharmaceuticals Private Limited. During the year the company acquired 100 of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48 of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017 the company acquired the trademarks UNION REUNION and BON UNION.Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer IPO price of Rs 603.In October 2017 Eris Lifesciences Ltd Eris acquired the entire shareholding of UTH Healthcare Ltd UTH for an allcash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity diabetes gestational diabetes mellitus maternal nutrition and cardiovascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.In December 2017 Eris Lifesciences Ltd Eris acquired the Indian branded formulations business of Strides Shasun Ltd Strides for an aggregate cash consideration of Rs 5000 crore. With this acquisition Eris acquired the marketing and distribution rights for India for 130 brands in the Neurology Psychiatry Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.During the year 2018 capital expenditure amounted to Rs 242.69 million. Additionally consideration of Rs. 5061.52 million was paid towards business acquisition.During the year 2018 UTH Healthcare Limited and Eris Healthcare Private Limited earlier known as Strides Healthcare Private Limited became subsidiaries of the Company.As on March 31 2019 the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries. During the year 2019 capital expenditure amounted to Rs 374.15 million. Additionally consideration of Rs. 107.22 million was paid towards business acquisition.In April 2019 the Company acquired the remaining shares of Kinedex Healthcare Private Limited thereby making it a wholly owned subsidiary. It launched new business divisions ErisART Nutriverse Aspire Oncosciences Filix and Allure. A newly constructed facility for softgel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets 41 mn capsules and 4 mn sachets. In December 2019 it launched Zomelis after acquiring the trademark from Novartis.As on March 31 2020 the Company has 5 five wholly owned subsidiaries. During the year 2020 the Company has acquired the remaining shares of Kinedex Healthcare Private Limited thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company Eris Pharmaceuticals Private Limited on 2nd June 2020. In Q3 FY 20 the Company launched Rariset under their inlicensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron.As on March 31 2021 the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021 two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited wholly owned subsidiary of the Company had incorporated a subsidiary company Eris Pharmaceuticals PrivateLimited on 2nd June 2020.In FY21. the Company strengthened portfolio with Gluxit its Dapagliozin brand in the strategically important SGLT 2 segment launched in October20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fastgrowing antithrombotics segment through the launch of Rivalto Rivaroxaban offering. It fortified portfolio with the launch of ZACD an immunityenhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands Serlift Desval ER Sonaxa and Levroxa while Serlift and Desval ER maintained theirranks in their respective segments.As on March 31 2022 the Company has 3 whollyowned subsidiaries and 2 other than wholly owned subsidiaries. During the year 2022 Eris Therapeutics Limited wholly owned subsidiary of the Company has been incorporated on 23rd June 2021. The Companys wholly owned subsidiary Eris M.J. Biopharm Private Limited Formerly known as Kinedex Healthcare Private Limited has issued fresh shares through private placement pursuant to which Eris holding is now 70 in Eris M.J. Biopharm Private Limited.In FY22 Company acquired a 100 stake in Oaknet Healthcare Ltd. for an Equity Valuation of Rs 6500 million. The business is housed in Eris Oaknet Healthcare Ltd. a 100 subsidiary of Eris. It launched human insulin through subsidiary Eris MJ Biopharm Ltd which houses jointventure partnership with MJ Biopharm a strategic partner in the insulin business. In Q4 FY 22 it launched Xsulin in the forms of vials and cartridges.

ERIS Lifesciences Ltd Share Price: ₹572.90 per share as on 24 Mar, 2023 04:01 PM
ERIS Lifesciences Ltd Market Capitalisation: ₹8,502.14Cr as of today
ERIS Lifesciences Ltd Revenue: ₹425.5Cr as on December 2022 (Q4 22)
ERIS Lifesciences Ltd Net Profit: ₹101.86Cr as on December 2022 (Q4 22)
ERIS Lifesciences Ltd Listing date: 10 Dec, 2017
ERIS Lifesciences Ltd Chairperson Name: Amit Indubhushan Bakshi